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KEY POINTS 
• Hypothyroidism is common in women of child-bearing age and commonly associated with adverse obstetric and offspring 
outcomes. 
• Pregnancy places substantial additional demands on the thyroid axis and women who have normal thyroid function prior to 
pregnancy may have insufficient reserve for pregnancy especially those with auto-immune thyroid disease 
• Levothyroxine is the treatment for hypothyroidism; in women established on levothyroxine prior to pregnancy doses will 
need increasing. 
• Screening for thyroid disease in pregnancy is being undertaken in some countries although this is a major debate in 
thyroidology at present. 
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SYNOPSIS 
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Thyroid hormone is essential for pregnancy and ensuring foetal development. Pregnancy also places substantial demands on the 
thyroid axis. Overt hypothyroidism is associated with substantial adverse obstetric and offspring outcomes and requires treatment. 
Borderline thyroid dysfunction (subclinical hypothyroidism and isolated hypothyroxinemia) are common in women and are associated 
with adverse obstetric and offspring outcomes although benefits of screening for and treating borderline thyroid function are less 
clear.  Many women are established on thyroid hormone replacement prior to pregnancy and doses will need increasing during 
pregnancy. Care needs to be taken to prevent over-replacement as this may offset benefits observed for IQ and may increase the risk 
of ADHD symptoms.  Universal thyroid screening in pregnancy is now being undertaken in several countries although it remains a 
matter of intense debate 
 
 
 
 
 
 
 
 
 
 
Introduction 
Adequate thyroid hormone is essential for maintaining a pregnancy and optimal fetal development
1
. During the first 
half of pregnancy, the fetus is entirely dependent on maternal thyroid hormone. Thyroid disorders, particularly low 
thyroid function are common in women of childbearing age and are frequently encountered in antenatal clinics. It 
is well established that overt hypothyroidism results in substantially higher risks of adverse pregnancy and offspring 
outcomes and all endocrine and obstetric societies recommend treating this.  Iodine is essential for thyroid hormone 
production so adequacy here is vital during pregnancy and in women of reproductive age.  There is now increasing 
evidence that even borderline thyroid function and thyroid auto-immunity are also associated with adverse outcomes 
raising the possibility that universal thyroid screening in pregnancy should be considered
2
. Furthermore, pregnancy 
places additional demands on the thyroid axis, so women with adequate thyroid hormone prior to pregnancy may 
fail to meet the additional demands of pregnancy.  
Clinically thyroid function is assessed by measuring the pituitary hormone - thyroid stimulating hormone (TSH) 
and thyroid hormone levels. The complex inverse relationship between TSH and thyroid hormone results in small 
changes in thyroid hormone levels causing larger changes in TSH. It is essential to measure thyroid hormone levels 
as well as TSH in order to differentiate between overt and subclinical thyroid disease.  
Iodine status and thyroid function 
Iodine is essential for the synthesis of thyroid hormones
3
. The recommended daily iodine intake in pregnancy has 
recently been increased to 250 μg/day which implies a urinary iodine excretion of 150– 250 μg/day as being 
adequate
4,5
. Iodine deficiency during pregnancy is associated with maternal goitre and results eventually in a reduced 
circulating maternal thyroxine concentration. These effects are preventable by iodine supplementation
6
  and benefits 
of this are observed only in both areas of severe iodine deficiency (24-h urinary iodine less than 50 μg) and also in 
areas of mild to moderate deficiency
7
. Children born to mothers with profound iodine deficiency show impaired 
neuro-intellectual development, sometimes to the extreme of cretinism in severely deficient states. These effects 
can be reduced by iodine administration before and even during gestation and this should be performed in areas of 
moderate to severe iodine deficiency
3
. It is noteworthy that even mild-moderate iodine deficiency in pregnant 
women is associated with adverse maternal effects including goitre
8
 and lower IQ in offspring
9
. Although a recent 
trial did not show benefit on iodine supplementation during pregnancy in areas of mild iodine deficiency
10
 further 
studies are required. Assessment of iodine status is challenging and urinary iodine remains an imperfect marker of 
iodine status serum thyroglobulin may become a useful biomarker of iodine status. Endocrine disruptors such as 
perchlorate, may exacerbate iodine deficiency and may also have a deleterious effect on offspring 
neurodevelopment
11,12
. 
Impact of pregnancy on the maternal thyroid status 
Pregnancy places substantial demands on the maternal thyroid axis these are summarized in Table 1 and Figure 1. 
The fetal thyroid is not functional until 18-20 weeks gestation so additional maternal thyroid hormone is required 
to meet this demand. Additionally there is increased thyroxine binding globulin and increased thyroid hormone 
degradation by placental type 3 deiodinase
13
 which also increases demands. There is also increased urinary iodine 
excretion during pregnancy. Urinary iodine excretion in pregnancy is maximal in the first trimester followed by a 
decline in the second and third trimesters. It is increasingly recognized that countries may have iodine sufficiency 
in the general population, but be insufficient for pregnancy
14
. As a result some countries can be iodine sufficient in 
the general adult population, but inadequate for pregnant women, the UK and Russia are notable examples of this
15
. 
This iodine deficiency can result in increased risk of maternal goitre as well as hypothyroidism. The pregnancy 
hormone beta hCG does stimulate the thyroid to produce thyroid hormone which will assist with meeting the 
increased demands on the thyroid axis in pregnancy. Recent data suggests that TPO antibody positive women may 
have an impaired thyroidal response to hCG
16
. This may explain why women with thyroid auto-immunity with 
positive thyroid peroxidase antibodies (TPO) have increased risk of adverse obstetric outcomes which can be 
independent of thyroid status. 
Assessment of thyroid status during pregnancy 
It is important to recognize that assessment of thyroid function in pregnancy is more complex than the general adult 
population. The above physiological changes in pregnancy have a substantial effect on the interpretation of thyroid 
function tests in pregnancy and result in a downward shift of TSH reference intervals. A pragmatic upper limit of 
2.5 mU/L was previously advocated for TSH but recent data now shows this threshold to be too low 
17
. One 
approach suggested in the current guidelines of the American Thyroid Association (ATA) is to set the pregnancy 
reference range at 0.5 mU/L and 0.4 mU/L below the upper and lower non-pregnant reference range respectively, 
reflecting the anticipated magnitude of the TSH drop 
18
. 
Current ATA guidelines advocate the use of pregnancy specific, local population-based reference ranges where 
possible;
18
 however it is well recognized that such data are not widely available. Assessment of thyroid function in 
pregnancy is also best done according to pregnancy specific reference-ranges calculated in a population of pregnant 
women free of key factors that interfere with thyroid function including women with known thyroid disease 
(including thyroid auto-immunity), use of thyroid altering medication, known iodine deficiency and high hCG states 
(twin pregnancies or IVF conception). However, it is also well established that normal thyroid status changes over 
pregnancy and accurate classification of thyroid function in pregnant women requires the use of gestational-age 
specific reference ranges
19
. There is also growing evidence that specific reference ranges may be considered based 
on ethnicity
20
, BMI
21
 and parity
21
.  
With respect to FT4, the most commonly used immunoassays are prone to biases in pregnancy due to changes in 
thyroid binding globulin and albumin concentrations
18,22
. Total T4 is a more predictable alternative as it typically 
rises by 50% of baseline values attaining peak levels by 16 weeks gestation 
18
. However Total T4 is less clearly 
associated with adverse outcomes so many clinicians prefer the use of FT4. More robust methods such as 
equilibrium dialysis, liquid chromatography-tandem mass spectrometry (LC-MS/MS), or FT4 index calculations are 
cumbersome to perform and not routinely used 
18
.  
Classification and epidemiology of thyroid abnormalities  
Overt hypothyroidism in pregnancy is defined as a TSH level above the pregnancy specific reference range and a 
low level of FT4. Although women established on levothyroxine make -up around 1% of pregnancies, newly 
diagnosed overt hypothyroidism occurs in approximately 0.2-0.6% of pregnant women
17,23
 . Treatment is mandatory 
as it is associated with profound adverse obstetric and offspring development outcomes.  The milder forms of low 
thyroid dysfunction are subclinical hypothyroidism (TSH above the population’s pregnancy reference range, but 
normal FT4) and isolated hypothyroxinemia (IH) (Normal TSH with FT4 in the lowest 2.5% of the reference range) 
and these are more common.  Subclinical hypothyroidism with an elevated TSH and normal FT4 concentrations—
can occur in up to 18% of pregnancies depending on the precise definition and TSH assay used. Observational 
studies have indicated that subclinical hypothyroidism is associated with adverse pregnancy outcomes, but not 
offspring neuro development. In contrast IH is associated with adverse outcomes with regard to offspring IQ and 
behavior, but less consistent associations have been observed for pregnancy outcomes.  
Overt hypothyroidism 
Overt hypothyroidism has been repeatedly associated with substantial adverse impacts on obstetric outcomes and 
fetal neuro development. Adverse obstetric outcomes include fetal loss, premature delivery, low birthweight and 
pre-eclampisa
23,24
. A large case-control study demonstrated that overt hypothyroidism resulted in a 7-point lower IQ 
than women with normal thyroid function
25
. It is worth noting, that women with adequately treated hypothyroidism 
have no higher risk of pregnancy complications, unlike those with untreated hypothyroidism indicating that thyroid 
status is a clearly reversible risk factor for adverse obstetric outcomes. 
Subclinical hypothyroidism 
Numerous studies have identified that subclinical hypothyroidism is associated with adverse pregnancy similar to 
overt hypothyroidism but as to be expected risk effects are more marginal. From meta-analyses subclinical 
hypothyroidism the following outcomes were all statistically  significant for adverse outcomes with (95%CI) 
provided. The odds of adverse outcomes are as follows - miscarriage (1.90 - 2.01) preterm delivery (1.20 – 1.81) 
growth restriction (1.54 – 3.36) pre-eclampsia (1.30 – 2.24) and gestational diabetes (1.28 – 4.33)26.  One problem 
has been with these analyses is that many studies have defined subclinical hypothyroidism differently. What is clear 
is that subclinical hypothyroidism does not appear to be associated with adverse neuro-behavioral outcomes in the 
offspring. 
Isolated hypothyroxinemia 
IH was originally considered to be a pregnancy-specific disease, reflecting a state of mild iodine deficiency. However, 
this has now been called into question as it also occurs in iodine sufficient areas. Other risk factors for IH include 
iron status, BMI and placental angiogenic factors
1
. IH has been associated with impaired offspring developmental 
outcomes 
27
 and has also been associated with offspring verbal delay
28
 autism
29
 and ADHD
30
 . In contrast to subclinical 
hypothyroidism it has not been consistently associated with adverse obstetric outcomes. 
Thyroid auto-immunity 
Anti-thyroid peroxidase antibodies are found in around 10% of otherwise normal pregnant women. They are a 
marker of thyroid auto-immunity and the main risk factor for thyroid dysfunction in pregnancy and in the 
postpartum period. Even in euthyroid women TPOAb positivity is associated with premature delivery and fetal loss 
although the exact mechanism remains unclear
31,32
 . One randomized controlled trial has shown that levothyroxine 
administration reduced the risk of fetal loss and premature delivery in euthyroid TPOAb-positive women
33
. A later 
study failed to replicate the benefits for fetal loss but did find a reduction in pre-term delivery
34
.  Women who are 
TPOAb positive are at an increased risk of thyroid-related adverse pregnancy outcomes, its interaction with higher 
TSH levels means it is likely that this risk is substantially increased in individuals who also have elevated TSH levels 
or those in the higher end of the normal range. As highlighted earlier women who are TPOAb positive have an 
impaired thyroidal response to beta hCG compared to women who are TPOAb negative this may explain its 
association with adverse obstetric outcomes and synergistic impact with higher TSH levels. 
Trials of Treatment with levothyroxine 
All endocrine and obstetric societies recommend treating overt hypothyroidism in pregnancy although there have 
been no recent trials in this area, but to have a control group here would be unethical.  To date three large 
randomized controlled trials have investigated the effects of screening for and treating borderline low thyroid 
function in pregnancy: these are the controlled antenatal thyroid screening (CATS) study 
35
, a study by Casey et al.
36
 
and a recent study by Nazarpour et al 
34
. These trials are summarized in Table 2.  The Nazarpour trial focused on 
preterm delivery and identified that levothyroxine may reduce the risk of preterm delivery in individuals with TSH 
levels > 4.0 mU/l (RR: 0.38; 95% CI: 0.15 to 0.98; p= 0.04)
34
. Offspring IQ was not assessed in this study. The two 
other large randomized controlled trials CATS
35
 and the study by Casey et al
37
 studied the effects of screening and 
treating borderline low thyroid function in pregnancy on offspring IQ and pregnancy outcomes. Neither study 
showed any beneficial effects of treatment on offspring IQ
35,37
. Reasons for failure to establish benefit aside from no 
treatment benefit, include the relatively late initiation of treatment (particularly in the Casey study) and early age of 
IQ assessment (particularly in the CATS study). It is worth highlighting that neurological development is crucial in 
the first 12 weeks of pregnancy.  Follow on analysis of the CATS study revealed no apparent benefit of treatment at 
age 9 although this was only performed in a subset also showed no treatment benefit. Work in the follow-up CATS 
study also identified levothyroxine over-treatment may increase the risk of autism symptoms
38
. More recent analysis 
using data linkage and the majority of the CATS cohort (to include those with normal thyroid function) identified 
that levothyroxine treatment significantly reduced the risk of miscarriage/still birth
38
. Similarly, another prospective 
study did identify that levothyroxine reduced the risk of miscarriage and pre-term birth
33
. However no benefit was 
observed with levothyroxine on obstetric outcomes in the Casey study although again this may be due to the relatively 
late initiation of treatment
37
.  
Treatment of established hypothyroidism in pregnancy 
Approximately 1% of pregnant women are established on levothyroxine prior to pregnancy.  In women established 
on levothyroxine prior to pregnancy, initial control in pregnancy is often sub-optimal 
39
 and may be associated with 
increased odds of foetal loss
39
,  and optimization should ideally occur prior to conception
40
. Women of child-bearing 
age on levothyroxine should be reminded to increase their pre-conception dose of levothyroxine by 30-50% as soon 
as pregnancy is confirmed. One approach is to take double their usual levothyroxine dose on 2 days of the week 
41
. 
It is worth noting, that dose increases are often higher in post-surgical or post-ablative hypothyroidism.  Women on 
levothyroxine should also be aware of important drug interactions with iron supplements and proton pump 
inhibitors in particular which can impair levothyroxine absorption. Other drugs to be aware of increase which 
increase levothyroxine clearance include carbamazepine, rifampicin and valproate. If overt hypothyroidism is 
diagnosed for the first time in pregnancy, we recommend starting a weight-based dose of 2mcg/kg a day. 
Close monitoring of thyroid function is essential in pregnancy we recommend to check thyroid function early in the 
first trimester and every 4-6 weeks thereafter. One should ideally aim for a TSH < 2.5mU/l in the first trimester and 
< 3 mU/l in later pregnancy. One should aim to ensure that the FT4 level is not too high and aim for the upper half 
of the reference range. There is some evidence that over-replacement with levothyroxine may increase ADHD 
symptoms and the relationship of FT4 and IQ is “U shaped” with both low -normal and high-normal FT4 are 
associated with lower IQ 
42
. After delivery we suggest returning levothyroxine to pre-conception dose and to recheck 
thyroid function at 6 weeks post-partum.  
Screening for and treating low thyroid function in pregnancy 
Universal thyroid screening in pregnancy remains contentious
2
. It is noteworthy that screening for and treating low 
thyroid function meets almost all the screening criteria laid down by Wilson and Jungner
43
. In particular it is an 
important asymptomatic health problem, with an accepted treatment and a suitable diagnostic test. It is also 
economically viable 
44
. However, at present it is still unclear what TSH threshold should be used for treatment in 
pregnancy and whether there should be a differential threshold based on TPO status. The criterion 8 “there should 
be an agreed policy on who to treat” is therefore not met. However, as there is widespread variation in clinical 
practice at present, this should not necessarily prevent the introduction of universal thyroid screening and indeed 
regular audit and review may establish more definitive treatment thresholds. Current ATA guidance takes into 
account the potential for interaction by TPO antibody status in its guidance, but did not recommended for or against 
universal thyroid screening
18
. This has not prevented some countries including Spain China and Poland from 
implementing universal thyroid screening. It is however accepted that targeted screening should be performed in 
those women at high risk for thyroid disease
18,45
 . Women deemed at high risk for thyroid disease in pregnancy 
include those with previous thyroid disease, a visible goitre, symptoms suggestive of hypo or hyperthyroidism, those 
with a family history of thyroid disease, those with a history of type 1 diabetes or other auto-immune conditions 
including positive thyroid antibodies, and women with a previous history of infertility, fetal loss or infertility. 
However this targeted approach would miss approximately one third of women with significant thyroid dysfunction
46
. 
This high risk screening approach has been further called into question as universal thyroid  screening is pregnancy 
appears to cost-effective; screening solely for overt hypothyroidism also had a cost-effectiveness ratio of 
$6,776/QALY (quality adjusted life-year)
44
 which is favorable compared to gestational diabetes mellitus screening 
($12,078/QALY) and is substantially below the $50,000/QALY figure used in the United States as a criterion for 
screening decisions. This work also indicated universal screening appears to be more cost-effective than targeted 
screening.  
  
Conclusion 
Despite the dramatic recent advances in our knowledge of thyroid physiology in pregnancy and the consequences 
of its variation, further research is still required. Delete need In particular prospective trials of early screening of 
thyroid function in pregnancy with both obstetric and developmental outcomes assessed. Continued advocacy of 
iodine sufficiency in pregnancy and assessment of endocrine disruptors are also needed. In current practice 
monitoring of thyroid function in early pregnancy needs urgent optimization.  
  
Table 1 Physiological changes that influence thyroid function in pregnancy 
 
  
Physiological change Effect on thyroid function 
test results 
Impact on interpretation of 
thyroid function tests 
↑ Thyroxine binding globulin 
↑ Serum Total T3 and T4 
concentrations 
 
Total thyroid hormone levels 
may be misleading -need to 
rely on free thyroid hormone 
levels 
↑ human chorionic 
gonadotrophin secretion 
↑ Free T4 and ↓ TSH 
 
High human chorionic 
gonadotrophin levels may 
result in gestational 
thyrotoxicosis. This usually 
only requires symptomatic 
treatment but needs to be 
distinguished from 
pathological thyroid disease. 
Response possibly impaired 
in TPO antibody positive 
women   
↑ Iodine excretion 
↓ Thyroid hormone 
production in iodine 
deficient 
areas 
 
Need to be mindful of iodine 
deficiency and ensure 
optimal intake ideally prior 
to conception 
↑ Plasma volume  
↑ T3 and T4 pool size 
 
Increased Type 3 5-
deiodinase (inner ring 
deiodination) activity from 
the placental  
 
↑ T3 and T4 degradation 
 May explain in part the 
increasing thyroid demand in 
pregnancy 
Thyroid enlargement (in 
some women) 
Increased thyroglobulin 
Small goitres are common in 
pregnancy, but may be a sign 
of low thyroid function so 
merits thyroid function 
testing 
Adapted from the Oxford Textbook of Diabetes and Endocrinology, Chapter 9.1 General considerations relating 
to thyroid disease in pregnancy by Peter N Taylor, LDKE Premawardhana, John H Lazarus 
 
 
 
 
 
Table 2 
 CATS Casey Nazarpour 
Year 2012 2017 2018 
Countries in trial UK, Italy USA Iran 
Number with low thyroid 
function randomised 
794 677 366 
Placebo-controlled No Yes No 
Gestational age at 
recruitment (weeks) 
Median (IQR) 
Screening 12.3  (11.6 -
13.6) 
Controls 12,3 (11.6 – 
13.5) 
 
 
Mean (SD) 
Screening 16.6 (3.0) 
Controls 16.7 (3.0) 
Mean (SD) 
Screening 11.4 (4.1) 
Controls 12.2 (4.3) 
Baseline TSH mU/l Median (IQR) 
Screening UK 3.8 (1.5-
4.7) 
Screening Italy 
3.1 (1.3-4.0) 
Controls UK 3.2 (1.2 – 
4.2) 
Controls Italy 
2,4 (1.3-3.9) 
Mean (95%CI) 
Screening 4.5 (4.4-4.7) 
Control 4.3 (4.2 -4.5) 
Median (IQR) 
Screening 3.8 (2.8-4.8) 
 
Outcomes assessed IQ age 3, IQ age 9 
Obstetric outcomes 
(analysed later and only in 
UK participants) 
Pregnancy outcomes, 
offspring IQ and 
behaviour 
Preterm delivery 
Benefit of levothyroxine No benefit with regard to 
IQ. Potential reduction in 
foetal loss. 
No benefits observed with 
regard to pregnancy 
outcomes and offspring 
IQ 
May reduce pre-term 
delivery at TSH levels > 
4.0 mU/l 
 
 
  
Figure 1 Effects of Pregnancy on thyroid function 
 
 
 
  
Figure 2 TSH FT4 and hCG levels over pregnancy. 
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